Xenon Pharmaceuticals (XENE) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic focus and pipeline overview

• Emphasis on neurology, with expertise in CNS ion channel drug development and a pipeline centered on potassium and sodium channel modulators.

• Lead asset ezetucalner (formerly XEN1101) targets epilepsy, showing strong efficacy and long-term safety in over 600 patient-years of exposure.

• Indication expansion includes major depressive disorder (MDD), with proof-of-concept data and a phase III trial planned for late 2024.

• Discovery pipeline includes Kv7, Nav1.1 (Dravet syndrome), and Nav1.7 (pain), with candidate selection ongoing and INDs expected from 2025 onward.

• Cash runway extends into 2027, fully funding late-stage programs and pipeline maturation.

Clinical development and data highlights

• Ezetucalner demonstrated best-in-class efficacy in epilepsy, with rapid onset and some patients achieving 12 months seizure freedom.

• MDD phase II (X-NOVA) showed dose response and rapid onset, with statistical significance on several depression scales, though narrowly missing on the primary endpoint due to sample size.

• Phase III MDD trials will use HAMD-17 as the primary endpoint, 1:1 randomization, and stricter inclusion criteria for more severe patients.

• Three phase III studies are planned for MDD, with risk mitigation strategies including larger sample sizes and third-party adjudication.

• Epilepsy phase III (X-TOLE 2) enrollment expected to complete late 2024 or early 2025, with top-line data 6–8 months after last patient screened.

Commercial and competitive positioning

• Ezetucalner offers a novel mechanism, rapid onset, and benefits for anhedonia and depressive symptoms, differentiating it from SSRIs/SNRIs and other epilepsy drugs.

• No significant sexual dysfunction or weight gain observed, addressing key side effects of current MDD therapies.

• Positioned for third-line or later use in epilepsy, targeting patients with unmet needs after generic therapies.

• Commercial launch in the U.S. planned independently, with a focused field team; ex-U.S. commercialization will involve partners.

• Competitive landscape monitored, but ezetucalner is the only potassium channel modulator with robust efficacy and long-term safety data in late-stage development.